BACKGROUND: The purpose of this study was to analyze the relationship between pretreatment inflammatory markers and the prognosis of patients with oropharyngeal, hypopharyngeal, and laryngeal cancers. METHODS: The data for 285 patients treated with curative intent by concurrent chemoradiotherapy (CRT) were obtained and their pretreatment inflammatory markers, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) were calculated. RESULTS: Significant relationships were observed between a high NLR and oropharyngeal or hypopharyngeal cancer, T3 to T4, N2b to N3, and clinical stage III to IV, whereas significant relationships were observed between a high LMR and laryngeal cancer, T1 to T2, and clinical stage I to II. With regard to survival outcomes, a high NLR, a high PLR, and a low LMR were all significantly associated with decreases in overall survival (OS) and disease-free survival (DFS). Furthermore, multivariate analysis showed that LMR was an independent prognostic factor. CONCLUSION: Pretreatment LMR was found to be an independent prognostic factor for patients with head and neck cancers treated by concurrent CRT.
BACKGROUND: The purpose of this study was to analyze the relationship between pretreatment inflammatory markers and the prognosis of patients with oropharyngeal, hypopharyngeal, and laryngeal cancers. METHODS: The data for 285 patients treated with curative intent by concurrent chemoradiotherapy (CRT) were obtained and their pretreatment inflammatory markers, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) were calculated. RESULTS: Significant relationships were observed between a high NLR and oropharyngeal or hypopharyngeal cancer, T3 to T4, N2b to N3, and clinical stage III to IV, whereas significant relationships were observed between a high LMR and laryngeal cancer, T1 to T2, and clinical stage I to II. With regard to survival outcomes, a high NLR, a high PLR, and a low LMR were all significantly associated with decreases in overall survival (OS) and disease-free survival (DFS). Furthermore, multivariate analysis showed that LMR was an independent prognostic factor. CONCLUSION: Pretreatment LMR was found to be an independent prognostic factor for patients with head and neck cancers treated by concurrent CRT.
Keywords:
chemoradiotherapy; head and neck cancer; lymphocyte-to-monocyte ratio (LMR); neutrophil-to-lymphocyte ratio (NLR); platelet-to-lymphocyte ratio (PLR)
Authors: Srikant Ambatipudi; Ryan Langdon; Rebecca C Richmond; Matthew Suderman; Devin C Koestler; Karl T Kelsey; Nabila Kazmi; Christopher Penfold; Karen M Ho; Wendy McArdle; Susan M Ring; Miranda Pring; Tim Waterboer; Michael Pawlita; Tom R Gaunt; George Davey Smith; Steve Thomas; Andy R Ness; Caroline L Relton Journal: Oral Oncol Date: 2018-09-05 Impact factor: 5.337
Authors: Uiju Cho; Hong Sik Park; So Young Im; Chang Young Yoo; Ji Han Jung; Young Jin Suh; Hyun Joo Choi Journal: PLoS One Date: 2018-07-26 Impact factor: 3.240